Select Language
PD-L1
PD-L1 Overview
| English Name | Programmed death-ligand 1 | Approved Drugs | 12 |
| Drugs in Clinical Trials | 153 | Target Synonym | HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen |
| Highest Development Stage | Approved | ||
| English Name | Programmed death-ligand 1 |
| Target Synonym | HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen |
| Approved Drugs | 12 |
| Drugs in Clinical Trials | 153 |
| Highest Development Stage | Approved |
PD-L1 Product List
- Product Category
Protein (27)Kits (3)Cell (4)Antibody (1)
- Product Status
Launched (35)
- Species
Human (19)Cynomolgus / Rhesus macaque (4)Mouse (6)Rabbit (3)Canine (2)Feline (1)
- Tag
His Tag (8)Fc Tag (5)Strep Tag (1)His Tag & Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (2)Fc Tag & Avi Tag (3)His Tag & Avi Tag (4)Llama IgG Fc Tag (1)Mouse IgG Fc Tag & Avi Tag (1)- (8)Tag Free (1)
- Conjugate
Unconjugated (18)Biotin-labeled (9)- (7)PE Labeled (1)
Add to Cart
Total: 35
- 1
- 2
- 3
- 4
PD-L1 Background
Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.
PD-L1 Synonyms
PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Brain metastases; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Oropharyngeal Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Lymphoma; Penile Neoplasms; Thymoma; Urogenital Neoplasms; Metastatic breast cancer; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Vaginal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Anus Neoplasms; Biliary Tract Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Nose Neoplasms; Ganglioglioma; Papillomavirus Infections; Carcinoma, Trans | Details |
| Erfonrilimab | KN-046; KN046; KNO-46 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Thymoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Thymus Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours | Details |
| Acasunlimab | PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 | Phase 3 Clinical | Genmab A/S, Biontech Se | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Radiation Pneumonitis; Acute Bronchitis; Pulmonary Disease, Chronic Obstructive; Lung Neoplasms | Details |
| PM-8002 | PM8002; PM-8002; BNT-327 | Phase 3 Clinical | Biotheus Inc | Solid tumours; Liver Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Neuroendocrine Tumors; Mesothelioma; Breast Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours; Neoplasms; Glioma | Details |
| PD-L1 t-haNK cell therapy | Phase 2 Clinical | Nantkwest Inc | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Pancreatic Neoplasms; Neoplasm Metastasis | Details | |
| RC-98 | RC-98; RC98; RC98-ADC | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Fallopian Tube Neoplasms; Breast Neoplasms; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Endometrial Neoplasms; Cholangiocarcinoma; Thymoma; Carcinoma, Squamous Cell; Castration-Sensitive Prostate Neoplasms; Thyroid Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Biliary Tract Neoplasms; Colonic Neoplasms; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Mesothelioma; Microsatellite instability-high cancer; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant | Details |
| RG-6084 | RG-6084; RO-7191863 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B, Chronic; Hepatitis B | Details |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 2 Clinical | Bristol-Myers Squibb Company | Leukemia, Myelogenous, Chronic; HIV Infections; Shock, Septic; Hodgkin Disease; Small Cell Lung Carcinoma; Neoplasms; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Evixapodlin | GS-4224; OX-4224 | Phase 2 Clinical | Gilead Sciences Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Danburstotug | STI-3031; STI-A1015; IMC-001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Neoplasm Metastasis | Details |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma | Details |
| HLX-43 | HLX-43; HLX43 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| IO-120/ IO-103 (IO Biotech) | IO-120/IO-103; IO-120+IO-103 | Phase 2 Clinical | Io Biotech Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms | Details |
| MAX-80391 | MAX-80391; MAX-8 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours | Details |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | Details |
| Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics Inc | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Lymphoma; Melanoma | Details |
| BPB-101 | BPB-101 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
| AB-001 (Agastiya Biotech) | AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech); AB01 (Agastiya Biotech) | Phase 2 Clinical | Agastiya Biotech LLC | Neoplasms | Details |
| 6MW-3511 | 6MW-3511 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
| 18F-BMS-986229 | 18F-BMS-986229; [18F]BMS-986229 | Phase 2 Clinical | Bristol-Myers Squibb International Corp, PeptiDream Inc | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| AP-505 | AP-505; B1962; AP505 | Phase 2 Clinical | AP Biosciences Inc | Solid tumours; Liver Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| sirpiglenastat | DRP-104 | Phase 2 Clinical | Dracen Pharmaceuticals Inc | Solid tumours; Fibrolamellar hepatocellular carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| LB-1410 | LB-1410 | Phase 2 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Solid tumours; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| HB-0028 | HB-0028 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | Details | |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | Details |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| LBL-024 | LBL024; LBL-024 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Solid tumours; Neoplasms; Carcinoma, Neuroendocrine | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Neoplasms | Details |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma | Details |
| INCB-099280 | INCB-099280; INCB-99280 | Phase 2 Clinical | Incyte Corp Ltd | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Mismatch Repair Deficient Cancer; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Microsatellite instability-high cancer; Mesothelioma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma | Details |
| FH-2001 | FH-2001 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Carrizumab | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details | |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Solid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular | Details |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms | Details |
| ADG-104 | ADG-104; ADG104 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc | Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms | Details |
| HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Sotiburafusp alfa | HB0025; HB-0025 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Kidney Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| IMM-2510 | IMM-2510; SYN-2510 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | Details | |
| PM-8003 | PM8003 | Phase 2 Clinical | Solid tumours | Details | |
| ABSK-043 | ABSK043 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| Lesabelimab | BC-003 | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd | Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms | Details |
| Emdifen | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences | Solid tumours | Details | |
| 89Zr-DFO-Atezolizumab | 89Zr-DFO-Atezolizumab | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Carcinoma, Renal Cell; Diagnostic agents | Details |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Carcinoma, Transitional Cell; Carcinoma, Basosquamous; Astrocytoma; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Solid tumours; Lymphoma, B-Cell; Neoplasms | Details |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 1 Clinical | Incyte Corp | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Opucolimab | HLX-20 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Neoplasms | Details |
| IMMH-010 | IMMH-010 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| Betifisolimab | MSB-2311 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours | Details |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Hematologic Neoplasms; Bone Marrow Neoplasms; Solid tumours; Neoplasms; Lymphoma, T-Cell; Lymphoma; Leukemia, Myeloid, Acute | Details |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Ovarian Neoplasms; Stomach Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details | |
| anti-PD-L1 CSR T-cell therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma; Neoplasms | Details | |
| anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Hormone-Resistant Prostate Neoplasms | Details | |
| AB-101 (Arbutus Biopharma) | AB-101 (Arbutus Biopharma) | Phase 1 Clinical | Arbutus Biopharma Corp | Hepatitis B, Chronic; Hepatitis B | Details |
| SIM-0237 | SIM-0237; SIM-237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qiyu Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms | Details |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | Details |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Hodgkin Disease; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| IBC-Ab002 | IBC-Ab002 | Phase 1 Clinical | ImmunoBrain Checkpoint Inc | Alzheimer Disease | Details |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company | Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | Details |
| DCR-PDL1 | DCR-PDL1 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours | Details |
| CVL006 | CVL006; B006 | Phase 1 Clinical | Fukang (Shanghai) Health Technology Co Ltd | Solid tumours; Neoplasms | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| LW-347 | LW-347 | Phase 1 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Neoplasms | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| PMI-06 | PMI06; PMI-06 | Phase 1 Clinical | Precision Molecular Inc | Carcinoma, Non-Small-Cell Lung | Details |
| YL-222 | YL222; YL-222 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasm Metastasis | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Numab Therapeutics Ag, Cstone Pharmaceuticals | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| SPX-303 | SPX-303 | Phase 1 Clinical | SparX Biopharmaceutical Corp | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Solid tumours | Details | |
| AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| 177Lu-RAD204 | RAD-204; 177Lu-RAD204; 177Lu-anti-PD-L1 sdAb | Phase 1 Clinical | Radiopharm Theranostics Ltd | Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| RAD-203 | RAD-203 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| HK-010 | HK-010; HK010 | Phase 1 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms | Details |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Serositis; Ascites | Details | |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
| HS-10386 | HS-10386 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | Details |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| SGN-PDL1V | SGN-PDL1V; PF-08046054 | Phase 1 Clinical | Seagen Inc | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Solid tumours; Neoplasms | Details |
| DR-30206 | DR-30206 | Phase 1 Clinical | Zhejiang Doer Biologics Corp | Solid tumours | Details |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| CS-23546 | CS-23546; CS23546 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Neoplasms; Immune System Diseases | Details |
| SG-1408 | SG-1408; SG1408 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours | Details |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | Imugene Ltd, City Of Hope National Medical Center | Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 1 Clinical | 3sbio Inc | Solid tumours; Composite Lymphoma; Neoplasms; Lymphoma | Details |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002; 68Ga-NOTA-SNA002 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours; Neoplasms; Contrast agents | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
| CN-202 | CN-202 | Phase 1 Clinical | Curon Biopharmaceutical Ltd | Solid tumours; Hematologic Neoplasms | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CA-170 | CA-170; AUPM-170 | Phase 1 Clinical | Aurigene | Solid tumours | Details |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| BR-102 | BR102 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Mabspace Biomedicine (Suzhou) Co Ltd | Solid tumours; Neoplasms; Papillomavirus Infections | Details |
| GS-19 | GT-90008; GS-19; GS-19-PLB-1C | Phase 1 Clinical | Gensun Biopharma Inc | Solid tumours | Details |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Solid tumours; Neoplasms | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Lymphoma | Details |
| Garivulimab | BGB-A333 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Neoplasms | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| CTB-1 | CTB-1 | Clinical | GTS Biotech LLC | Neoplasms | Details |
| 89Zr-KN035（Wuxi No. 4 People's Hospital） | Clinical | Wuxi No. 4 People | Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Socazolimab | ZKAB001; STI-A1014; STIA-1014; ZKAB-001; STI-1014 | Approved | Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd, Sorrento Therapeutics Inc | 善克钰 | Mainland China | Uterine Cervical Neoplasms | Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | 2023-12-19 | Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Melanoma | Details |
| Pyrvinium Pamoate | Approved | Povan | United States | null | 1956-01-01 | Helminthiasis; Stomach Neoplasms; Pancreatic Neoplasms; Metaplasia; Enterobiasis; Carcinoma, Pancreatic Ductal | Details | |||
| Envafolimab | KN-035; ASC-22 | Approved | Suzhou Alphamab Co Ltd, 3d Medicines (Sichuan) Co Ltd | ENWEIDA, 恩维达 | Mainland China | Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer | 3d Medicines (Sichuan) Co Ltd | 2021-11-25 | Sepsis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Sarcoma; Microsatellite instability-high cancer; Colonic Neoplasms; Dermatofibrosarcoma; Solid tumours; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Hepatitis B, Chronic; Carcinoma, Renal Cell; Esophageal Neoplasms; Shock, Septic; Liver Neoplasms; HIV Infections | Details |
| Atezolizumab | RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A; RG-7446-42 | Approved | Genentech Inc | 泰圣奇, Tecentriq | United States | Carcinoma, Non-Small-Cell Lung | Genentech Inc | 2016-05-18 | Urologic Neoplasms; Urogenital Neoplasms; Metastatic breast cancer; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Lymphoproliferative Disorders; Sezary Syndrome; Colorectal Neoplasms; Penile Neoplasms; Oropharyngeal Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Lymphoma, Follicular; Osteosarcoma; Sarcoma; Urethral Neoplasms; Breast Neoplasms; Thymoma; Gastrointestinal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Liposarcoma, Myxoid; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms, Unknown Primary; Lymphoma, T-Cell, Cutaneous; Laryngeal Neoplasms; Endometrial Neoplasms; Glioma; Carcinoma, Squamous Cell; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcin | Details |
| Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | United States | Carcinoma, Merkel Cell | Emd Serono Inc | 2017-03-23 | Leukemia, Myeloid, Acute; Lymphoma, Extranodal NK-T-Cell; Microsatellite Instability; Osteosarcoma; Peritoneal Neoplasms; Testicular Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Sezary Syndrome; Carcinoma, Neuroendocrine; Lymphoma, T-Cell; Fallopian Tube Neoplasms; Testicular Diseases; Penile Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Adenoid Cystic; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma, Large-Cell, Anaplastic; Thymoma; Carcinoma, Pancreatic Ductal; Lymphoma; Neoplasms, Germ Cell and Embryonal; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Meningioma; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Lymphoma, B-Cell; Ovarian Neoplasms; Lymphoma, T-Cell, Peripheral; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Gonadal Disorders; Neoplasms; Hodgkin Disease; Na | Details |
| Tagitanlimab | KL-A167; A-167; HBM-9167 | Approved | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 科泰莱 | Mainland China | Nasopharyngeal Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2024-12-25 | Solid tumours; Lymphoma, B-Cell; Hodgkin Disease; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Carcinoma, Non-Small-Cell Lung | Details |
| Adebrelimab | HTI-1316; SHR-1316; HTI-1088 | Approved | Jiangsu Hengrui Medicine Co Ltd, Atridia Pty Ltd | 艾瑞利 | Mainland China | Small Cell Lung Carcinoma | Shanghai Suncadia Medicine Co Ltd | 2023-02-28 | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Esophageal Squamous Cell Carcinoma; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Ovarian Diseases; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Nasopharyngeal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms | Details |
| Durvalumab | 28X28X9-OKV (UNII code); MEDI-4736 | Approved | Medimmune Llc | 英飞凡, Imfinzi | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Uk Ltd | 2018-02-16 | Primary Myelofibrosis; Esophageal adenocarcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Testicular Neoplasms; Sezary Syndrome; Leukemia, Myeloid, Acute; Pinealoma; Ureteral Neoplasms; Urologic Neoplasms; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Laryngopharyngitis; Microsatellite Instability; Sarcoma; Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Mycosis Fungoides; Laryngeal Diseases; Dysgerminoma; Carcinoma, Endometrioid; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Vulvar Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell, Cutaneous; Appendiceal Neoplasms; Uterine Neoplasms; Thyroid Neoplasms; Gallbl | Details |
| Cosibelimab | TG-1501; CK-301 | Approved | Dana-Farber Cancer Institute | UNLOXCY, Unloxcyt, UNLOXCIT | United States | Carcinoma, Squamous Cell | Checkpoint Therapeutics Inc | 2024-12-13 | Head and Neck Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Sugemalimab | WBP-3155; CS-1001 | Approved | Cstone Pharmaceuticals (Suzhou) Co Ltd | ZEJIEMEI, Cejemly, 择捷美 | Mainland China | Carcinoma, Non-Small-Cell Lung | Cstone Pharmaceuticals (Suzhou) Co Ltd | 2021-12-20 | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lymphoma, T-Cell; Lymphoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Prostatic Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Hodgkin Disease; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours | Details |
| Atezolizumab/Hyaluronidase | Approved | Genentech Inc | TECENTRIQ HYBREZA | United States | Sarcoma, Alveolar Soft Part; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma | Genentech Inc | 2024-09-12 | Small Cell Lung Carcinoma; Sarcoma, Alveolar Soft Part; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details | |
| Benmelstobart | CBT-502; APL-502; TQ-B2450; TQB2450; TQB-2450 | Approved | Cbt | 安得卫 | Mainland China | Small Cell Lung Carcinoma | Sino Biopharmaceutical Ltd | 2024-04-30 | Esophageal Squamous Cell Carcinoma; Primary mediastinal B cell lymphoma; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Bile Duct Neoplasms; Genital Neoplasms, Female; Peritoneal Neoplasms; Endometrial Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Sarcoma; Lung Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Adenocarcinoma; Esophageal Diseases; Carcinoma, Hepatocellular; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Lymphoma, B-Cell; Biliary Tract Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Hepatitis B, Chronic; Gastrointestinal Diseases; Digestive System Diseases; Esophageal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Neoplasms, Squamous Cell; Hodgkin Disease; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Digestive System Neoplasms; Lymphoma, Extranodal NK-T-Cell | Details |
Product Reviews
W***G2025-11-07
0People LikePurchased ACRO's protein, customer service response is fast, shipping and logistics are also very fast. Conducted activity testing after receiving the protein, the data fully met my expectations, experiments progressed very smoothly, overall impression is great, will support ACRO.- C***z2025-04-30 0People LikeWe are always very satisfied with the reagents ordered from ACRO!
- A***n2024-10-18 0People LikeWe order at Acrobiosystems for ELISA/ECL reagents. Up to now, we are happy with their products (quality) and the support they provide to us. It is quick to have a quote and very fast shipment.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland